Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: Enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 3090-3101

  Zhu, Rongrong ^a   Cheng, Ka Wing ^a   MacKenzie, Gerardo ^a   Huang, Liqun ^a   Sun, Yu ^a   Xie, Gang ^a   Vrankova, Kveta ^a   Constantinides, Panayiotis P ^b   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Medicon Pharmaceuticals Inc   (United States)

Author keywords

lung cancer; mitochondria targeting; non steroidal anti inflammatory drugs; phospho sulindac; solid lipid nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; ISOPROSTANE DERIVATIVE; OXT 328; PHOSPHOSULINDAC; SOLID LIPID NANOPARTICLE; SULINDAC; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; DRUG TUMOR LEVEL; EMULSION; EVAPORATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRION; MOUSE; NANOENCAPSULATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TARGET CELL DESTRUCTION; TUMOR XENOGRAFT; URINE LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; LIPIDS; LUNG NEOPLASMS; MICE; MICE, NUDE; MITOCHONDRIA; NANOPARTICLES; ORGANOPHOSPHORUS COMPOUNDS; SULINDAC; SUPEROXIDES; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867851229     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0801-x     Document Type: Article

References (36)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-80.
2. Haanen C. Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001;2(5):677-83.
3. Malkinson AM. Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res. 2005;31(1):57-82.
4. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis. 1997;18(5):1001-6.
5. Castonguay A, Rioux N. Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis. 1997;18(3):491-6.
6. Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, et al. The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol. 2011;162(7):1521-33.
7. Xie G, Nie T, Mackenzie G, Sun Y, Huang L, Ouyang N, et al. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol. 2011;165(7):2152-66.
8. Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, et al. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res (Phila). 2011;4(7):1052-60.
9. Huang L, Zhu C, Sun Y, Xie G, Mackenzie GG, Qiao G, et al. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis. 2010;31(11):1982-90.
10. Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, et al. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology. 2010;139(4):1320-32.
11. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
12. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-96.
13. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300.
14. Zara GP, Cavalli R, Fundaro A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res. 1999;40(3):281-6.
15. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res. 2000;42(4):337-43.
16. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target. 2002;10(4):327-35.
17. Reddy LH, Adhikari JS, Dwarakanath BS, Sharma RK, Murthy RR. Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice. AAPS J. 2006;8(2):E254-62.
18. Jain SK, Chaurasiya A, Gupta Y, Jain A, Dagur P, Joshi B, et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul. 2008;25(5):289-97.
19. Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA. Lipid-based drug delivery systems for cancer treatment. Curr Drug Targets. 2011;12(8):1151-65.
20. Kozoni V, Tsioulias G, Shiff S, Rigas B. The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen. Carcinogenesis. 2000;21(5):999-1005.
21. Naito A, Carcel-Trullols J, Xie CH, Evans TT, Mizumachi T, Higuchi M. Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line. Int J Cancer. 2008;122(7):1506-11.
22. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell. 2003;112(4):481-90.
23. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010;48(6):749-62.
24. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol. 1992;5(2):227-31.
25. Tanaka T, Hosoi F, Yamaguchi-Iwai Y, Nakamura H, Masutani H, Ueda S, et al. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J. 2002;21(7):1695-703.
26. Attama AA. SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat Drug Deliv Formul. 2011;5(3):178-87.
27. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71(3):409-19.
28. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9(6):447-64.
29. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87(1):99-163.
30. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Comm. 2010;396(1):120-4.
31. Nonn L, Williams RR, Erickson RP, Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol. 2003;23(3):916-22.
32. Hansen JM, Zhang H, Jones DP. Mitochondrial thioredoxin-2 has a key role in determining tumor necrosis factor-alpha-induced reactive oxygen species generation, NF-kappaB activation, and apoptosis. Toxicol Sci. 2006;91(2):643-50.
33. Zhang R, Al-Lamki R, Bai L, Streb JW, Miano JM, Bradley J, et al. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res. 2004;94(11):1483-91.
34. Sun Y, Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res. 2008;68(20):8269-77.
35. Kozoni V, Rosenberg T, Rigas B. Development of novel agents based on nitric oxide for the control of colon cancer. Acta Pharmacol Sin. 2007;28(9):1429-33.
36. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007;2:221-6.